Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis

1. Abraham, C. & Cho, J. H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066–2078 (2009).

   Google Scholar 

2. Elinav, E. & Peer, D. Harnessing nanomedicine for mucosal theranostics–a silver bullet at last? ACS Nano 7, 2883–2890 (2013).

   Google Scholar 

3. Olesen, M. T., Ballarín-González, B. & Howard, K. A. The application of RNAi-based treatments for inflammatory bowel disease. Drug Deliv. Transl. Res. 4, 4–18 (2014).

   Google Scholar 

4. Castanotto, D. & Rossi, J. J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426–433 (2009).

   Google Scholar 

5. Shinn. J. et al. Oral nanomedicines for siRNA delivery to treat inflammatory bowel disease. Pharmaceutics 14, 1969 (2022).

6. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet 23, 265–280 (2022).

   Google Scholar 

7. Zhou, X. et al. In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis. Nat. Commun. 13, 5700 (2022).

   Google Scholar 

8. Dammes, N. et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat. Nanotechnol. 16, 1030–1038 (2021).

   Google Scholar 

9. Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K. & Saltzman, W. M. A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 14, 239–247 (2015).

   Google Scholar 

10. Zhao, Y. et al. A temporally resolved DNA framework state machine in living cells. Nat. Mach. Intell. 5, 980–990 (2023).

    Google Scholar 

11. Zhan, P. et al. Recent advances in DNA origami-engineered nanomaterials and applications. Chem. Rev. 123, 3976–4050 (2023).

    Google Scholar 

12. Pitikultham, P. et al. Stimuli-responsive DNA origami nanodevices and their biological applications. ChemMedChem 17, e202100635 (2022).

    Google Scholar 

13. Wagenbauer, K. F. et al. Programmable multispecific DNA-origami-based T-cell engagers. Nat. Nanotechnol. 18, 1319–1326 (2023).

    Google Scholar 

14. Wang, Y. et al. A DNA robotic switch with regulated autonomous display of cytotoxic ligand nanopatterns. Nat. Nanotechnol. 19, 1366–1374 (2024).

    Google Scholar 

15. Hellmeier, J. et al. Strategies for the site-specific decoration of DNA origami nanostructures with functionally intact proteins. ACS Nano 15, 15057–15068 (2021).

    Google Scholar 

16. Wang, Z. et al. A tubular DNA nanodevice as a siRNA/chemo-drug co-delivery vehicle for combined cancer therapy. Angew. Chem. Int Ed. Engl. 60, 2594–2598 (2021).

    Google Scholar 

17. Yin, J. et al. An intelligent DNA nanodevice for precision thrombolysis. Nat. Mater. 23, 854–862 (2024).

    Google Scholar 

18. Li, L. et al. A DNA origami device spatially controls CD95 signalling to induce immune tolerance in rheumatoid arthritis. Nat. Mater. 23, 993–1001 (2024).

    Google Scholar 

19. Li, S. et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 36, 258–264 (2018).

    Google Scholar 

20. Liu, S. et al. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat. Mater. 20, 421–430 (2020).

    Google Scholar 

21. Mol, C. D., Izumi, T., Mitra, S. & Tainer, J. A. DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination [corrected]. Nature 403, 451–456 (2000).

    Google Scholar 

22. Sheng, C. et al. Spatially resolved in vivo imaging of inflammation-associated mRNA via enzymatic fluorescence amplification in a molecular beacon. Nat. Biomed. Eng. 6, 1074–1084 (2022).

    Google Scholar 

23. Nath, S. et al. The extracellular role of DNA damage repair protein APE1 in regulation of IL-6 expression. Cell Signal 39, 18–31 (2017).

    Google Scholar 

24. Sheng, C., Zhao, J., Yu, F. & Li, L. Enzyme translocation-mediated signal amplification for spatially selective aptasensing of ATP in inflammatory cells. Angew. Chem. Int Ed. Engl. 62, e202217551 (2023).

    Google Scholar 

25. Hu, Q., Li, H., Wang, L., Gu, H. & Fan, C. DNA nanotechnology-enabled drug delivery systems. Chem. Rev. 119, 6459–6506 (2019).

    Google Scholar 

26. Wang, P. et al. Visualization of the cellular uptake and trafficking of DNA origami nanostructures in cancer cells. J. Am. Chem. Soc. 140, 2478–2484 (2018).

    Google Scholar 

27. Parton, R. G. & Simons, K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 8, 185–194 (2007).

    Google Scholar 

28. van Loo, G. & Bertrand, M. J. M. Death by TNF: a road to inflammation. Nat. Rev. Immunol. 23, 289–303 (2023).

    Google Scholar 

29. Zhang, C. et al. Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy. Sci. Adv. 8, eabp9882 (2022).

    Google Scholar 

30. Hsu, N. Y. et al. NOX1 is essential for TNFα-induced intestinal epithelial ROS secretion and inhibits M cell signatures. Gut 72, 654–662 (2023).

    Google Scholar 

31. Zhang, T. et al. Transcription factor EB modulates the homeostasis of reactive oxygen species in intestinal epithelial cells to alleviate inflammatory bowel disease. Biochimica et. Biophysica Acta Mol. Basis Dis. 1870, 167065 (2024).

    Google Scholar 

32. Bourgonje, A. R. et al. Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease. Trends Mol. Med. 26, 1034–1046 (2020).

    Google Scholar 

33. Zhou, J. et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nat. Commun. 13, 3432 (2022).

    Google Scholar 

34. Bao, M. et al. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease. Acta Biomater. 161, 250–264 (2023).

    Google Scholar 

35. Jiang, D. et al. DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat. Biomed. Eng. 2, 865–877 (2018).

    Google Scholar 

36. Li, R. Q. et al. A DNA-based and bifunctional nanomedicine for alleviating multi-organ injury in sepsis under diabetic conditions. Acta Biomaterialia 177, 377–387 (2024).

    Google Scholar 

37. Chen, Q. et al. Sequential therapy of acute kidney injury with a DNA nanodevice. Nano Lett. 21, 4394–4402 (2021).

    Google Scholar 

38. Li, W. et al. A DNA nanoraft-based cytokine delivery platform for alleviation of acute kidney injury. ACS Nano 15, 18237–18249 (2021).

    Google Scholar 

39. Duan, X. et al. Radiolabeling and preliminary evaluation of (99m)Tc-labeled DNA cube nanoparticles as potential tracers for SPECT imaging. Int. J. Nanomed. 16, 5665–5673 (2021).

    Google Scholar 

40. Tollemeto, M. et al. Topology determines DNA origami diffusion in intestinal mucus. Nano Lett. 25, 16060–16067 (2025).

41. Kurmaeva, E. et al. T cell-associated α4β7 but not α4β1 integrin is required for the induction and perpetuation of chronic colitis. Mucosal. Immunol. 7, 1354–1365 (2014).

    Google Scholar 

42. Kihara, N. et al. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 52, 713–719 (2003).

    Google Scholar 

43. Zhang, T. et al. Plant green pigment of chlorophyllin attenuates inflammatory bowel diseases by suppressing autophagy activation in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 323, G102–g113 (2022).

    Google Scholar 

44. Li, W. et al. DNA-based hydrogels with multidrug sequential release for promoting diabetic wound regeneration. JACS Au 3, 2597–2608 (2023).

    Google Scholar 

Download references

Author notes

1. These authors contributed equally: Tianci Zhang, Ruoqing Li.

Authors and Affiliations

1. Chongqing Key Laboratory of Emergency Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, China

   Tianci Zhang, Ruoqing Li & Wei Li

2. Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, China

   Tianci Zhang & Nanwei Tong

3. Department of General Medicine, Chongqing Key Laboratory of Emergency Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, China

   Ruoqing Li & Yi Jiang

4. The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institute, Stockholm, Sweden

   Zhenghao Wang

5. Department of Endocrinology and Metabolism, Research Center for Islet Transplantation, West China Hospital, Sichuan University, Chengdu, China

   Ye Zhou

6. Animal Laboratory Center, West China Hospital, Sichuan University, Chengdu, China

   Yaojia Zhou & Xiaoting Chen

7. Core Facility, West China Hospital, Sichuan University, Chengdu, China

   Cui Peng

Contributions

T.Z. and R.L. contributed equally to the work. T.Z. and R.L., and W.L. conceived the project, designed the experiments and wrote the manuscript. T.Z., R.L., Z.W., Y.Z., Y.Z., X.C., and C.P. performed the experiments and analyzed the data. Y.J., N.T., and W.L. revised the manuscript.

Corresponding authors

Correspondence to Yi Jiang, Nanwei Tong or Wei Li.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Communications thanks Chen-Yu Zhang and the other anonymous reviewer for their contribution to the peer review of this work. A peer review file is available.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions